Skip to content
lifestyle.theroguemag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Vector Sciences & Therapeutics
Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides
August 20, 2026
/C O R R E C T I O N — Vector Sciences & Therapeutics/
August 19, 2026
Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings
August 17, 2026
Vector Science & Therapeutics Corp., LyoGenesis Plus and Wynn Pharmaceuticals Announce Strategic Collaboration to Develop and Manufacture Critical Care Medical Products
July 28, 2026
Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
July 24, 2026
Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor
June 8, 2026
Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy
June 2, 2026
/C O R R E C T I O N — Vector Sciences & Therapeutics/
May 24, 2026
Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing
May 24, 2026
Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC
May 23, 2026
1
2
Next Page
→